Aprea Therapeutics

Aprea Therapeutics presented early clinical data at the H.C. Wainwright conference on its oral WEE1 inhibitor showing dose-dependent responses, including a first partial response at 150 mg and a confirmed partial response at 220 mg. The safety profile was described as unusually favorable for heavily pretreated patients, which could facilitate combination studies. Funding of $41 million is expected to secure the cash runway into the first quarter of 2028; the company is concentrating investments on the WEE1 program and seeking a partner for the ATR inhibitor. Additional data, including results from the 300 mg cohort, are expected in the coming quarters. » More on de.investing.com

Aprea Therapeutics announces an intellectual property portfolio of 28 granted patents and 30 pending applications. The WEE1 program, including the lead candidate APR-1051 (Phase-1 study ACESOT-1051), is covered by multiple US and non‑US filings; potential exclusivity could extend to 2047. The ATR program has issued US and non‑US patents and pending applications that, if granted, could provide protection through 2045. Aprea has deprioritized development of ATRN-119 as monotherapy in favor of APR-1051 and will instead evaluate ATRN-119 in combination therapies. » More on de.investing.com

Aprea Therapeutics will present data from the ongoing phase‑1 study ACESOT‑1051 of APR‑1051 at a scientific conference in Q4 2026. Dose escalation is currently in the 300 mg cohort (10–500 mg planned), and the number of active sites has been increased from three to ten, which is expected to raise the recruitment rate to six to ten patients per month by Q4 2026. The program will be expanded to include combinations with standard therapies in HPV‑positive head-and-neck squamous cell carcinoma and colorectal cancer; recruitment will also be expanded to at least 50 patients with serous endometrial carcinoma or cyclin‑E–overexpressing, platinum‑resistant ovarian cancer. Completion of dose escalation and the backfill expansion is expected in Q2 2027. » More on de.investing.com